Hubert Andrew

Dr. Hubert Andrew


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2022 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
SPStephanie Amabella Prayogo
Stephanie Amabella Prayogo
HAHubert Andrew
Hubert Andrew
SCStefanny Cong
Stefanny Cong
KIKadek Devi Aninditha Intaran
Kadek Devi Aninditha Intaran
Introduction: Condylomata acuminata (CA) is a sexually transmitted infection with a high prevalence associated with psychosexual morbidity in both men and women of various age. Up to now, treatment modalities yield low clearance and recurrence rate (RR) and are also deemed low quality evidence-wise. Photodynamic therapy (PDT) is a novel and promising therapy to effectively cure and prevent CA recurrence. Method: This systematic review was reported according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) and registered to the International Prospective Register of Systematic Review (PROSPERO) (CRD42022332760). Results: Ten studies were included in this systematic review. A significant value of complete response (CR) ranging from 63–100% in patients with genital warts after receiving several sessions of PDT. A relatively low recurrence rate was seen in all 10 studies, with an RR of less than 17%. Quality assessment of included studies reported mostly high-quality research. Conclusions: PDT therapy resulted in a higher CR with significantly lower RR compared to other therapies. Thus, PDT can be an alternative treatment of CA with low RR and minimal side effects. Additional research, especially randomized clinical trials in various countries, is needed to further substantiate this treatment and formulate definitive protocols.

22 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AHAgo Harlim
Ago Harlim
HAHubert Andrew
Hubert Andrew
CHChastine Harlim
Chastine Harlim
Background: Liquid injectable silicone (LIS) is controversially used for soft-tissue augmentation, frequently causing severe, late-onset foreign body granulomas. Complete surgical removal is nearly impossible due to silicone migration, with residues leading to high recurrence. Meanwhile, medical therapies alone do not address macroscopic structural deformity. This study evaluates a combined protocol of subdermal granulectomy followed by adjuvant intralesional steroids for chin siliconomas. Methods: An ambidirectional cohort study (2015–2025) evaluated 35 patients with LIS-induced chin granulomas. All subjects underwent submental granulectomy. Postoperatively, patients were allocated to an adjuvant steroid cohort (n = 17) or a surgery-only control cohort (n = 18). The outcomes included aesthetic improvements (chin shape and erythema) and recurrence-free survival. Results: Granulectomy yielded significant improvements in aesthetics (p = 0.001) and erythema (p < 0.001) with a 2.86% complication rate. Longitudinal survival analysis demonstrated that adjuvant steroids lowered the crude recurrence rate (5.89% vs. 44.4%, p = 0.018) and significantly extended recurrence-free survival (Log-rank p = 0.016). The surgery-only cohort exhibited higher recurrence risk (Cox hazard ratio = 8.59, p = 0.043). Over the follow-up period, the surgery-only cohort experienced significant aesthetic deterioration (p = 0.04) and persistent redness, whereas the steroid cohort preserved postsurgical chin shape (p = 0.19) and achieved further erythema reduction (p = 0.03). Multivariable regression indicated higher odds of aesthetic preservation (adjusted odds ratio [aOR] = 3.85, p = 0.082) and erythema resolution (aOR = 2.90, p = 0.145) in the steroid cohort, although statistical significance was not reached. Conclusions: Our subdermal granulectomy technique successfully removed macroscopic silicone burden while maintaining the appearance of the anterior chin. The implementation of an early adjuvant steroid protocol provides a synergistic advantage by neutralizing residual microscopic inflammation, delaying recurrence, and ensuring durable aesthetic outcomes.

1 July 2026 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Closed access
AHAgo Harlim
Ago Harlim
HPHulman Panjaitan
Hulman Panjaitan
HAHubert Andrew
Hubert Andrew
CHChastine Harlim
Chastine Harlim
Context: Delayed inflammatory reactions at cosmetic implant sites have been reported after coronavirus disease 2019 vaccination, but population-level data from Indonesia remain limited. Aims: To estimate the prevalence of self-reported implant-site inflammatory reactions after coronavirus disease 2019 vaccination among cosmetic implant users in Indonesia and to explore associated factors. Methods: A cross-sectional online survey was distributed in Indonesia from November 2021 to July 2022. Respondents receiving at least one coronavirus disease 2019 vaccine dose who reported having a cosmetic implant were included. The primary outcome was self-reported localized redness, swelling, or pain at the implant site rather than clinically verified foreign-body reaction. Results: Among 1,610 valid responses, 266 respondents reported having cosmetic implants. Implant-site inflammatory reactions were reported by 10 respondents, corresponding to a period prevalence of 3.76% (95% CI: 1.82–6.80%). Adverse vaccine reactions were reported by 91 respondents (34.2%). An exploratory analysis suggested these respondents had higher odds of implant-site inflammatory reactions (OR: 4.78; 95% CI: 1.21–18.94; p = 0.04). However, this finding must be interpreted cautiously because only 10 events were observed and multivariable adjustment was not possible. No significant association was observed with age, sex, or vaccine type. Conclusions: A small proportion of respondents with cosmetic implants reported implant-site inflammatory symptoms following coronavirus disease 2019 vaccination. Because outcomes were self-reported, derived from a cross-sectional design, and key confounders were unmeasured, causal interpretation remains uncertain. These findings should be interpreted strictly as hypothesis-generating pharmacovigilance evidence. Prospective, clinically validated studies incorporating detailed implant characterization and reaction timing are required.